
1. proc natl acad sci u a. 2014 jan 7;111(1):421-6. doi: 10.1073/pnas.1321704111. 
epub 2013 dec 16.

epstein-barr virus nuclear antigen 3c binds batf/irf4 spi1/irf4 composite
sites recruits sin3a repress cdkn2a.

jiang s(1), willox b, zhou h, holthaus am, wang a, shi tt, maruo s, kharchenko
pv, johannsen ec, kieff e, zhao b.

author information: 
(1)department medicine, brigham women's hospital, program virology,
department microbiology immunobiology, center biomedical
informatics, harvard medical school, boston, 02115.

epstein-barr virus nuclear antigen 3c (ebna3c) repression cdkn2a p14(arf) 
p16(ink4a) essential immortal human b-lymphoblastoid cell line (lcl)
growth. ebna3c chip-sequencing identified >13,000 ebna3c sites lcl dna. most
ebna3c sites associated active transcription; 64% strong h3k4me1- 
and h3k27ac-marked enhancers 16% active promoters marked h3k4me3 
h3k9ac. using encode lcl transcription factor chip-sequencing data, ebna3c sites 
coincided (±250 bp) runx3 (64%), batf (55%), atf2 (51%), irf4 (41%), mef2a
(35%), pax5 (34%), spi1 (29%), bcl11a (28%), sp1 (26%), tcf12 (23%), nf-κb (23%),
pou2f2 (23%), rbpj (16%). ebna3c sites separated five distinct clusters:
(i) sin3a, (ii) ebna2/rbpj, (iii) spi1, (iv) strong (v) weak batf/irf4.
ebna3c signals positively affected runx3, batf/irf4 (aice) spi1/irf4 
(eice) cooccupancy. gene set enrichment analyses correlated ebna3c/sin3a promoter
sites transcription down-regulation (p < 1.6 × 10(-4)). ebna3c signals 
strongest batf/irf4 spi1/irf4 composite sites. ebna3c bound strongly to
the p14(arf) promoter spi1/irf4/batf/runx3, establishing rbpj-, sin3a-,
and rest-mediated repression. ebna3c immune precipitated sin3a and
conditional ebna3c inactivation significantly decreased sin3a binding the
p14(arf) promoter (p < 0.05). data support model ebna3c binds
strongly batf/irf4/spi1/runx3 sites enhance transcription recruits
rbpj/sin3a- rest/nrsf-repressive complexes repress p14(arf) p16(ink4a)
expression.

doi: 10.1073/pnas.1321704111 
pmcid: pmc3890834
pmid: 24344258  [indexed medline]

